Key result
Sacubitril/valsartan lowers CD4+/CD8+ ratio and improves LVEF vs. standard therapy in heart failure.
Why the study?
The immunomodulatory effects of sacubitril/valsartan on CD4+/CD8+ T-cell ratio and extracellular matrix remodeling in heart failure are not fully elucidated.
Does the addition of sacubitril/valsartan to standard heart failure therapy improve cardiac function, biomarkers, and the CD4+/CD8+ T-cell ratio in patients with heart failure with reduced ejection fraction?
RCT (n=20)
Randomized
No
Does the addition of sacubitril/valsartan to standard heart failure therapy improve cardiac function, biomarkers, and the CD4+/CD8+ T-cell ratio in patients with heart failure with reduced ejection fraction?
Sacubitril/valsartan therapy is associated with improvements in cardiac function and a reduction in the CD4+/CD8+ T-cell ratio, suggesting an immunomodulatory mechanism may contribute to its beneficial effects in heart failure.
Answers are grounded in this paper and cite their sources.
Supports adding sacubitril/valsartan in HF for cardiac and immunomodulatory benefits; extends evidence to T-cell ratio modulation in this RCT.
Heart failure (HF) remains a global health challenge with complex pathophysiology. The CD4+/CD8 + T-cell ratio represents a potential immune marker. While sacubitril/valsartan (SV) has demonstrated clinical benefits in HF treatment, its modulatory effects are not fully elucidated. This clinical study enrolled 20 HF patients who were randomly assigned to receive either standard guideline‑directed therapy with β‑blockers plus aldosterone receptor antagonists (BB + ARA) or BB + ARA plus SV (BB + ARA+SV group) for three months. Cardiac function, biomarkers, and T-cell subsets were assessed to evaluate the effects of SV on HF progression. CD8⁺ T-cell proportions in peripheral blood were measured by flow cytometry. A doxorubicin (DOX) induced HF mouse model was established with three groups (Control, DOX, DOX + SV). Cardiac function was evaluated by echocardiography. Histopathological changes were analyzed via hematoxylin-eosin and Masson staining. CD4 expression was detected by immunohistochemistry, and TGF-β1 expression was assessed by immunofluorescence. mRNA and protein expression levels were measured by RT-qPCR and western blot. Bioinformatics analysis (identification of differentially expressed genes and enriched pathways from public HF datasets) was performed to explore potential causal links between modifications in the pathway and the protective effects of SV. SV significantly improved left ventricular ejection fraction, reduced left ventricular end-diastolic diameter, brain natriuretic peptide, N-terminal pro-B-type natriuretic peptide, and decreased the CD4+/CD8 + ratio compared with both baseline and the BB + ARA control group. In DOX-induced mice, SV improved cardiac function, reduced fibrosis, inflammatory infiltration, CD4 + T-cell accumulation, and significantly suppressed TGF-β1 expression in myocardial tissues. Bioinformatic analysis highlighted extracellular matrix (ECM)-receptor interaction as a key pathway, and in vivo, SV downregulated matrix metalloproteinase (MMP)2 and MMP9, while upregulating tissue inhibitor of metalloproteinase-1. SV treatment is associated with a reduced CD4+/CD8 + T-cell ratio and suppressed pathological ECM remodeling via the ECM-receptor interaction pathway, suggesting a potential immunomodulatory contribution to its therapeutic effects in HF.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) conducted an RCT in Heart Failure (n=20). Sacubitril/valsartan vs. Beta-blockers + aldosterone receptor antagonists was evaluated on CD4+/CD8+ T cell ratio. Sacubitril/valsartan added to standard therapy significantly reduced the CD4+/CD8+ T-cell ratio and improved left ventricular ejection fraction compared to standard therapy alone in heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: